Ritvo E R, Freeman B J, Yuwiler A, Geller E, Yokota A, Schroth P, Novak P
J Pediatr. 1984 Nov;105(5):823-8. doi: 10.1016/s0022-3476(84)80316-9.
Fenfluramine was administered to 14 outpatient children with the syndrome of autism to determine whether previously produced decreases in blood serotonin concentrations and clinical improvements could be reinstituted. A double-blind medication-placebo crossover design was used. Each patient received fenfluramine 1.5 mg/kg daily (0.75 mg/kg twice daily) for 8 months, followed by placebo for 2 months. Blood serotonin levels promptly fell approximately 49% regardless of baseline levels. Clinical improvement returned, and on some scales gains after 8 months exceeded those noted after only 4 months of treatment. Significant correlations emerged among the amount of clinical response, initially high verbal IQs, and low blood serotonin concentrations. Compliance was excellent, and no clinically relevant side effects or weight changes occurred. It appears that fenfluramine is effective in ameliorating specific symptoms in certain autistic patients. The extent and mechanism of its action remain to be discovered.
对14名患有自闭症综合征的门诊儿童使用芬氟拉明，以确定之前出现的血液血清素浓度降低和临床改善情况是否能够重现。采用双盲药物 - 安慰剂交叉设计。每位患者每天服用1.5毫克/千克芬氟拉明（0.75毫克/千克，每日两次），持续8个月，随后服用2个月安慰剂。无论基线水平如何，血液血清素水平迅速下降约49%。临床改善情况重现，在某些量表上，8个月后的改善超过仅治疗4个月时的情况。临床反应程度、最初较高的言语智商和较低的血液血清素浓度之间出现了显著相关性。依从性良好，未出现临床相关的副作用或体重变化。看来芬氟拉明对改善某些自闭症患者的特定症状有效。其作用程度和机制仍有待发现。
